RecruitingPhase 1Phase 2NCT06417554

A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors

A Phase IB /II, Multicenter, Open-Label Study of Safety, Tolerability and Efficacy of SHR-A2102 for Injection With or Without Antitumor Therapy in Subjects With Advanced Solid Tumors

Sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd.

Enrollment

80 participants

Start Date

May 13, 2024

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumors

Summary

The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 for injection with or without Antitumor Therapy in Advanced Solid Tumors. To explore the reasonable dosage of SHR-A2102 for Advanced Solid Tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called SHR-A2102 and a drug called SHR-A2102 ; Adebrelimab injection for people with advanced solid tumors. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.